- Oyster Point Pharma, Inc.

Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences, Establishing New Viatris Eye Care Division

Read more about Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences, Establishing New Viatris Eye Care Division

Oyster Point Pharma to Present New Scientific Analyses at World Cornea Congress VIII

Read more about Oyster Point Pharma to Present New Scientific Analyses at World Cornea Congress VIII

Oyster Point Pharma to Present Analyses at the Women in Ophthalmology Summer Symposium

Read more about Oyster Point Pharma to Present Analyses at the Women in Ophthalmology Summer Symposium

Oyster Point Pharma Research Selected for Top 5 Poster Session at American Optometric Association's Optometry's Meeting®

Read more about Oyster Point Pharma Research Selected for Top 5 Poster Session at American Optometric Association's Optometry's Meeting®

Oyster Point Pharma to Present New Analyses at the Association for Research in Vision and Ophthalmology (ARVO) 2022

Read more about Oyster Point Pharma to Present New Analyses at the Association for Research in Vision and Ophthalmology (ARVO) 2022

Oyster Point Pharma to Present New Clinical Data at the American Society of Cataract and Refractive Surgery (ASCRS) 2022

Read more about Oyster Point Pharma to Present New Clinical Data at the American Society of Cataract and Refractive Surgery (ASCRS) 2022

Oyster Point Pharma Announces Publication in Ophthalmology of ONSET-2 Phase 3 Data on TYRVAYAᵀᴹ (varenicline solution) Nasal Spray

Read more about Oyster Point Pharma Announces Publication in Ophthalmology of ONSET-2 Phase 3 Data on TYRVAYAᵀᴹ (varenicline solution) Nasal Spray

Oyster Point Pharma to Present Data at the American Academy of Ophthalmology Annual Meeting 2021

Read more about Oyster Point Pharma to Present Data at the American Academy of Ophthalmology Annual Meeting 2021

Oyster Point Pharma to Present Data at the American Academy of Optometry Annual Meeting 2021

Read more about Oyster Point Pharma to Present Data at the American Academy of Optometry Annual Meeting 2021

Oyster Point Pharma Announces FDA Approval of TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease

Read more about Oyster Point Pharma Announces FDA Approval of TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease

© 2023 Oyster Point Pharma, Inc., TYRVAYA™, and the Oyster Point logo are trademarks of Oyster Point Pharma, Inc.